Loading...
  • humoral
  • Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. (duke.edu)
  • isolate
  • Antibody-Virus Co-Evolution Project - a collaborative project of the Duke CHAVI-ID and the NIH Vaccine Research Center to isolate the evolution pathways of all known specificities of HIV-1 broadly neutralizing antibodies (BnAbs) and the evolution pathways of the founder HIV-1 virus that induced BnAbs in individuals with HIV-1 infection. (chavi-id-duke.org)
  • immune
  • Virus-like particles (VLPs) have gained increasing interest for their use as vaccines due to their repetitive antigenic structure that is capable of efficiently activating the immune system. (isharonline.org)
  • Adjuvant - a pharmacological agent that is added to a vaccine to enhance the immune response of the vaccine recipient. (chavi-id-duke.org)
  • Understanding the expression patterns of key innate immune modulators will be useful in assessing the disease state and potential rates of disease progression in HIV + patients, which could lead to novel therapy and vaccine approaches. (pubmedcentralcanada.ca)
  • Scientists report that melanoma patients receiving denileukin diftitox immediately prior to a dendritic cell-vaccine failed to develop a tumor-antigen-specific CD4 and CD8 T cell immune response even after repeated vaccinations. (humanimmunologynews.com)
  • challenge
  • One possible explanation for the emergence of SIVmac239-like sequences in these two epitopes was that recombination had occurred between the vaccine and challenge viruses. (nih.gov)
  • We also noted that the consensus sequence of the challenge stock differed from the vaccine construct in 10 amino acids including 3 changes in the V4 loop. (nih.gov)
  • effective
  • The propensity of HIV to utilize mucosal transmission to spread to new hosts suggests that developing an effective HIV vaccine will likely require an in-depth understanding of these earliest events at the mucosal sites, as well as the subsequent events that follow at other tissue sites such as lymph nodes (LN) and blood. (pubmedcentralcanada.ca)
  • animals
  • The results demonstrated that VSV-vectored GM-CSF abrogated the protective effect of the vaccine, since 4 of 6 animals were protected in gag-env group, whereas addition of GM-CSF reduced protection to 1 of 6 animals in gag-env-GM-CSF group as previously reported . (nih.gov)
  • strategy
  • B Cell Lineage Vaccine Design - a vaccine strategy of the Duke CHAVI-ID that is based on targeting the unmutated common ancestor (UCA) and intermediate antibody (IA) of broadly neutralizing antibody lineages using Envs or Env subunits that are designed to optimally bind to UCAs and IAs. (chavi-id-duke.org)
  • cells
  • Our overall hypothesis is that monocytes/macrophages from HIV+ patients will be impaired in their ability to carry out functional responses essential to Mtb killing compared to uninfected cells and cells taken from SIV natural host monkey species (i.e. sooty mangabeys) that do not exhibit clinical signs of sAIDS. (fredhutch.org)